Detalhe da pesquisa
1.
Isoniazid Monoresistance and Antituberculosis Treatment Outcome in Persons With Pulmonary Tuberculosis in Brazil.
Open Forum Infect Dis
; 11(1): ofad691, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38221983
2.
Impact of adverse drug reactions on the outcomes of tuberculosis treatment.
PLoS One
; 18(2): e0269765, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36749743
3.
Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil.
PLoS One
; 14(6): e0217014, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31170171
4.
Cutaneous tuberculosis in Rio de Janeiro, Brazil: description of a series of 75 cases.
Int J Dermatol
; 58(12): 1451-1459, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31553059
5.
Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial.
Biomed Res Int
; 2018: 9231835, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30792988
6.
Impact of adverse drug reactions on the outcomes of tuberculosis treatment
Artigo
em Inglês
| ARCA | ID: arc-58411
7.
Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study
Artigo
em Inglês
| ARCA | ID: arc-51593
8.
Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil
Artigo
em Inglês
| ARCA | ID: arc-33819
9.
Cutaneous tuberculosis in Rio de Janeiro, Brazil: description of a series of 75 cases
Artigo
em Inglês
| ARCA | ID: arc-37644
10.